A Phase 1, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease
Latest Information Update: 17 May 2021
At a glance
- Drugs Lorecivivint (Primary)
- Indications Intervertebral disc degeneration
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biosplice Therapeutics
- 19 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 02 Aug 2018 Planned End Date changed from 1 Jul 2018 to 18 Nov 2018.
- 02 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 18 Nov 2018.